Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial.

Abstract

BACKGROUND:

Triflusal has demonstrated an efficacy similar to aspirin in the prevention of vascular events in patients with acute myocardial infarction (ΜΙ) and ischaemic stroke but with less bleeding events.

OBJECTIVE:

We performed a randomised, multicentre, phase 4 clinical trial to compare the clinical efficacy and safety of triflusal versus aspirin, administered for 12 months in patients eligible to receive a cyclooxygenase-1 (COX-1) inhibitor.

METHODS:

Patients with stable coronary artery disease or with a history of non-cardioembolic ischaemic stroke were randomly assigned to receive either triflusal 300 mg twice or 600 mg once daily or aspirin 100 mg once daily for 12 months. The primary efficacy endpoint was the composite of: (a) ΜΙ, (b) stroke (ischaemic or haemorrhagic), or, (c) death from vascular causes for the entire follow-up period. The primary safety endpoints were the rate of bleeding events as defined by Bleeding Academic Research Consortium (BARC) criteria.

RESULTS:

At 12-month follow-up, an equivalent result was revealed between the triflusal (n=559) and aspirin (n=560) in primary efficacy endpoint. Specifically, the combined efficacy outcome rate (i.e. MI, stroke or death from vascular causes) difference was equal to -1.3% (95% confidence interval -1.1 to 3.5) and lied within the a-priori defined equivalence interval (p<0.001). Regarding the primary safety endpoints, patients on triflusal treatment were 50% less likely to develop bleeding events according to the BARC criteria, and especially any clinically overt sign of haemorrhage that requires diagnostic studies, hospitalisation or special treatment (BARC type 2).

CONCLUSION:

The efficacy of triflusal in the secondary prevention of vascular events is similar to aspirin when administered for 12 months. Importantly, triflusal significantly reduced the incidence of ΜΙ and showed a better safety profile compared with aspirin. (ASpirin versus Triflusal for Event Reduction In Atherothrombosis Secondary prevention, ASTERIAS trial; Clinical Trials.gov Identifier: NCT02616497).

• Authors: Kallirroi I Kalantzi, Ioannis V Ntalas, Vasileios G Chantzichristos, Maria E Tsoumani, Dimitrios Adamopoulos, Christos Asimakopoulos, Adamantios Bourdakis, Petros Darmanis, Alexandra Dimitriadou, Stefanos Gkiokas, Konstantinos Ipeirotis, Kyriaki Kitikidou, Ioannis Klonaris, Aglaia Kostaki, Dimitrios Logothetis, Konstantinos Mainas, Theodoros Mais, Athanasios Maragiannis, Konstantina Martiadou, Konstantinos Mavronasos, Ioannis Michelongonas, Dimitrios Mitropoulos, Georgios Papadimitriou, Achilleas Papadopoulos, Miltiadis Papaioakeim, Kosmas Sofillas, Sotiria Stabola, Emmanouil Stefanakis, Dimitrios Stergiou, Maria Thoma, Alexandros Zenetos, Stergios Zisekas, John A Goudevenos, Demosthenes B Panagiotakos, Alexandros D Tselepis
• Journal: Current vascular pharmacology (Curr Vasc Pharmacol) Vol. 17 Issue 6 Pg. 635-643 ( 2019) ISSN: 1875-6212 [Electronic] United Arab Emirates
• PMID: 29866011 (Publication Type: Clinical Trial, Phase IV, Comparative Study, Equivalence Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
• Copyright: Copyright© Bentham Science Publishers; For any queries, please email at [email protected].

Chemical References

• Cyclooxygenase Inhibitors
• Platelet Aggregation Inhibitors
• Salicylates
• triflusal
• Aspirin

Topics

• Aged
• Aspirin (adverse effects, therapeutic use)
• Brain Ischemia (diagnosis, mortality, prevention & control)
• Coronary Artery Disease (diagnosis, drug therapy, mortality)
• Cyclooxygenase Inhibitors (adverse effects, therapeutic use)
• Female
• Greece
• Hemorrhage (chemically induced)
• Humans
• Intracranial Embolism (diagnosis, mortality, prevention & control)
• Male
• Middle Aged
• Myocardial Infarction (diagnosis, mortality, prevention & control)
• Platelet Aggregation Inhibitors (adverse effects, therapeutic use)
• Recurrence
• Risk Factors
• Salicylates (adverse effects, therapeutic use)
• Secondary Prevention
• Stroke (diagnosis, prevention & control)
• Time Factors
• Treatment Outcome